You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Can Early Lung Cancer Screening Improve Long-Term Survival Rates?

  • Authors: News Author: Marcia Frellick; CME Author: Charles P. Vega, MD
  • CME / ABIM MOC / CE Released: 1/27/2023
  • Valid for credit through: 1/27/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.25 ABIM MOC points

    Nurses - 0.25 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)

    Pharmacists - 0.25 Knowledge-based ACPE (0.025 CEUs)

    Physician Assistant - 0.25 AAPA hour(s) of Category I credit

    IPCE - 0.25 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for primary care physicians, pulmonary medicine specialists, oncologists, cardiothoracic surgeons, nurses/nurse practitioners, pharmacists, physician assistants and other clinicians who treat and manage patients at high risk for lung cancer.

The goal of this activity is for members of the healthcare team to be better able to compare survival rates based on the stage of screening-detected lung cancer.

Upon completion of this activity, participants will:

  • Assess the basis of recommendations from the US Preventive Services Task Force for screening for lung cancer
  • Compare 10-year survival rates based on tumor stage among adults with lung cancer found on screening
  • Outline implications for the healthcare team


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


News Author

  • Marcia Frellick

    Freelance writer, Medscape

    Disclosures

    Marcia Frellick has no relevant financial relationships.

CME Author

  • Charles P. Vega, MD

    Health Sciences Clinical Professor of Family Medicine
    University of California, Irvine School of Medicine

    Disclosures

    Charles P. Vega, MD, has the following relevant financial relationships:
    Consultant or advisor for: GlaxoSmithKline; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Editor/Nurse Planner

  • Lisa Simani, APRN, MS, ACNP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Compliance Reviewer

  • Yaisanet Oyola, MD

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Yaisanet Oyola, MD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE

This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Contact This Provider

    For Nurses

  • Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.00 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number: JA0007105-0000-23-022-H01-P).

    Contact This Provider

  • For Physician Assistants

    Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 01/27/2024. PAs should only claim credit commensurate with the extent of their participation.

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Can Early Lung Cancer Screening Improve Long-Term Survival Rates?

Authors: News Author: Marcia Frellick; CME Author: Charles P. Vega, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 1/27/2023

Valid for credit through: 1/27/2024, 11:59 PM EST

processing....

Clinical Context

The US Preventive Services Task Force (USPSTF) now recommends routine screening for lung cancer with an annual low-dose computed tomography (LDCT) study of the lungs among patients between 50 and 80 years of age with at least a 20 pack-year history of cigarette smoking, provided that they currently smoke or quit within the past 15 years. Jonas and colleagues provided the review that helped the USPSTF make its latest decision regarding screening for lung cancer, and their results were published in a manuscript for the Agency for Healthcare Research and Quality.[1]

There have been 2 landmark trials of screening for lung cancer among high-risk adults. An American study found significant 11% and 7% reductions in lung cancer mortality and overall mortality among patients after 3 rounds of annual LDCT screening vs chest radiography. Meanwhile, a study of LDCT screening vs no screening in Europe found a 25% reduction in lung cancer mortality after 4 rounds of screening, but no benefit for overall mortality.

Sensitivity of LDCT in the detection of lung cancer exceeded 80% in most studies, and specificity was more than 75%. The authors elucidated a rate of 17 invasive procedures for false-positive LDCT results for every 1000 individuals screened.

Screening for lung cancer is only beneficial if the treatment of early-stage tumors results in better outcomes. The current study examines mortality rates after the detection of localized lung cancer.

Study Synopsis and Perspective

Discovering lung cancer early with annual low-dose computed tomography greatly improves long-term survival rates to 80%, findings from a 20-year international study indicate.

Claudia Henschke, MD, PhD, professor of radiology and director of the Early Lung and Cardiac Action Program (ELCAP) at the Icahn School of Medicine at Mount Sinai in New York City, presented research results at the Radiological Society of North America (RSNA) 2022 Annual Meeting.

The researchers studied lung cancer-specific survival (LCS) of 87,416 participants enrolled in an international, prospective study named the International Early Lung Cancer Action Program (I-ELCAP).

Lung cancer is the leading cause of cancer death. The American Lung Association states that the average 5-year survival rate is 18.6%. Only 16% of the cancers are caught early, and more than half of people with lung cancer die within a year of diagnosis.

Participants’ 20-Year Survival Rate 80%

Results of this large, international study, however, showed that the overall 20-year survival rate for the 1285 screening participants diagnosed with early-stage cancer was 80% (95% CI, 77%-83%). Among the 1285 patients diagnosed, 83% had stage 1 cancer, Dr Henschke said.

For baseline screening, a positive result on the initial low-dose CT scan was defined as the identification of at least one solid or partially solid noncalcified nodule that is ≥ 5mm, at least one nonsolid noncalcified pulmonary nodule 8mm or more in diameter, or a solid endobronchial nodule. If none of the noncalcified nodules identified met the study criteria for a positive result or if the test was negative, CT was repeated 12 months later.[2]

LCS was 100% for the 139 participants with nonsolid nodule consistency and for the 155 participants with part-solid consistency. LCS was 73% (95% CI, 69%-77%) for the 991 participants with solid consistency, and for clinical stage IA participants LCS was 86% (95% CI, 83%-89%), regardless of consistency.

For participants with pathologic stage IA lung cancer 10 mm or less in average diameter, the 20-year survival rate with identification and resection was 92% (95% CI, 87%-96%).

No lung cancer deaths were identified in the part-solid and nonsolid cancers, the researchers report.

These results show that the 10-year findings from 2006 published in the New England Journal of Medicine, which also showed 80% survival rates (95% confidence interval, 74 to 85) with LDCT, have persisted, Dr Henschke said.[2]

At the time of the 2006 paper, 95% of Americans diagnosed with lung cancer died from it, she added.

Dr Henschke notes that by the time symptoms appear, lung cancer is often advanced, so the best tool for detecting early-stage lung cancer is enrolling in an annual screening program. When cancer is small enough and can be surgically removed, patients can be effectively cured long-term, she added.

“In the future, perhaps blood markers will allow us to detect it in the first half of the life cycle of lung cancer instead of CT at the beginning of the second half of the life cycle,” Dr Henschke said.

“The study raises the power of prospective data collection in the context of clinical care, as recommended by the Institute of Medicine long ago,” she noted.

Findings “Very Promising”

Ernest Hawk, MD, MPH, head of the Division of Cancer Prevention and Population Sciences at the University of Texas MD Anderson Cancer in Houston, told Medscape Medical News the findings look “very promising.” Dr Hawk was not involved in the study.

“This was one of the earliest studies to evaluate [LDCT] scanning. Their report that the initial benefits seem to be holding up over a longer period of observation is great,” he said.

“This bolsters the data that lung cancer screening is beneficial over a longer period of observation,” he added, noting that most of the randomized controlled trials have been shorter.

Lung cancer screening is now recommended for high-risk individuals--those with at least a 20-pack-year history of tobacco use who are between 50 and 80 years old.

So far, screening is still limited to people at high risk, Dr Hawk said, although there is discussion about whether benefit would extend to people exposed to asbestos, for instance, or secondhand smoke.

“The biggest challenge right now is getting the screening to those who actually meet the criteria,” Dr Hawk said.

Medscape Medical News reported earlier this month that less than 6% of high-risk smokers have the recommended annual lung cancer screening, according to a new report from the American Lung Association.[3]

Dr Henschke is on the Advisory Board for LungLifeAI and is on the board for the Early Diagnosis and Treatment Research Foundation. Dr Hawk has disclosed no relevant financial relationships.

Radiological Society of North America (RSNA) 2022 Annual Meeting. Abstract S4-SSCH02-3. Presented November 27, 2022.

Study Highlights

  • According to the 2006 report, 31,567 asymptomatic adults at least 40 years of age underwent baseline LDCT screening between 1993 and 2005. All participants had a risk factor for lung cancer, with cigarette smoking being the most common. However, adults with particulate exposure and secondhand smoke exposure were also included. A total of 27,456 follow-up screenings were conducted after the initial LDCT scan.
  • The mean age of participants was 61 years, and the average number of pack-years was 30.
  • LDCT was considered positive after the first screen for findings of at least 1 solid or partly solid noncalcified pulmonary nodule at least 5 mm in diameter, at least 1 nonsolid noncalcified pulmonary nodule at least 8 mm in diameter, or at least 1 endobronchial nodule.
  • There was a dedicated protocol for the management of positive LDCT results. Participants with a negative initial LDCT were encouraged to repeat screening in 12 months.
  • The main study outcome was mortality associated with stage I lung cancer detected by screening. Stage 1 lung cancer was defined by T0M0 status and an adenocarcinoma less than 30 mm in diameter. A board of experts reviewed all cases to ensure that they were not more advanced cancer.
  • Rates of abnormal LDCT were 13% at baseline and 5% during follow-up testing. A total of 405 cases of lung cancer were found on initial screening, and 74 on subsequent screening.
  • The median tumor diameter was 13 mm at baseline and 9 mm at subsequent screenings.
  • 411 patients with lung cancer were treated with resection, and 57 received radiation, chemotherapy, or both. Sixteen patients did not receive treatment for lung cancer.
  • The 10-year survival rate for all participants with lung cancer was 80% (95% CI, 74 to 85). The operative mortality rate was 0.5%.
  • 85% of participants with cancer had a stage I tumor. The 10-year survival rate among participants with stage I cancer was 88% (95% CI, 84 to 91). The respective survival rate was even higher among participants with stage I cancer who underwent surgery within 1 month of diagnosis, at 92% (95% CI, 88 to 95)

Clinical Implications

  • Two landmark trials of screening for lung cancer among high-risk adults have resulted in a USPSTF recommendation for routine screening. An American study found significant 15% and 7% reductions in lung cancer mortality and overall mortality among patients after 3 rounds of annual LDCT screening vs chest radiography. Meanwhile, a study of LDCT screening vs no screening in Europe found a 25% reduction in lung cancer mortality after 4 rounds of screening, but no benefit for overall mortality. Sensitivity of LDCT in the detection of lung cancer exceeded 80% in most studies, and specificity was more than 75%.
  • 10-year survival for any screening-detected lung cancer in the current study was 80%. But this rate was 88% in an analysis limited to adults with stage I lung cancer only, and it rose to 92% if these patients underwent surgery within 1 month.
  • Implications for the healthcare team: The healthcare team should promote LDCT among older adults with a significant history of smoking. The discovery of early-stage cancer improves survival outcomes.

 

Earn Credit

  • Print